NTHI — NEONC TECHNOLOGIES HOLDINGS, INC.

Nasdaq · Health Care · Pharmaceuticals · CIK 1979414 ·
Last close
$5.14
Market Cap
$133.71M
52W High
$10.42
52W Low
$3.87
ADV30
90,313
Next earnings
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -7,008,539 -8,819,932 3,330,161 138,601 16,561,326
Dec 2025 0 -13,625,675 -15,524,104 2,823,634 58,729 20,331,363
Sep 2025 0 -6,934,647 -8,615,920 4,082,916 1,513,224 15,897,186
Jun 2025 0 -5,708,034 -5,680,170 2,988,187 125,039 14,803,681

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-20,363,949
Investing CF
Financing CF
$20,857,784
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
$-2.97
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-112,754,655
Inventory
Receivables
ST Investments
EBIT TTM
$-65,317,614
Pretax Income TTM
$-67,822,181
Interest Exp TTM
$2,504,567
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$0
EBITDA
Free Cash Flow
$-1,603,043
Enterprise Value
$135,395,776
Total Cash
$138,601
Total Debt
$346,053
Shares Out
26,013,136
Trailing EPS
$-1.77
Book Value
$-0.80
ROE
ROA
-354.6%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 39,990 -58,169,198 -62,146,210 2,823,634 20,331,363 -20,363,948
Dec 2024 83,000 -7,142,522 -11,898,464 3,417,241 8,922,202 -4,213,916
Dec 2023 70,462 -8,097,669 -14,921,065 1,265,376 15,253,629 -1,880,012
Dec 2022 20,000 -2,837,604 -3,046,757 728,682 2,304,093 -881,736

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.64

Peers — same industry

TickerNameMarket CapLastDaily %
GNLX GENELUX Corp $134.97M $3.01
CNTB Connect Biopharma Holdings Ltd $135.65M $2.40
DERM Journey Medical Corp $131.79M $6.12
VTVT vTv Therapeutics Inc. $130.61M $33.16
MSLE Satellos Bioscience Inc. $141.76M $6.80

News headlines (Yahoo Finance, 1h cache)

NeOnc Provides Business Update and Reports Q1 2026 Financial Results
2026-05-18 13:00 · Yahoo
Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6
2026-05-14 15:39 · Yahoo
NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts
2026-05-05 13:00 · Yahoo
New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM EST - Show #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Gro
2026-04-18 14:00 · Yahoo
NeOnc Technologies Holdings, Inc. Announces ~ $300,000 in Insider Purchases of NTHI Stock by Chairman and CEO; Company Provides Context on 2025 Financial Results
2026-04-14 13:00 · Yahoo
NeOnc Provides Business Update and Reports Q4 2025 Financial Results
2026-04-01 13:00 · Yahoo
NeOnc Technologies Appoints David Choi as Chief Accounting Officer
2026-03-13 13:00 · Yahoo
Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI)
2026-03-12 12:52 · Yahoo
NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m.
2026-03-04 13:00 · Yahoo
NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity
2026-02-27 14:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.